Menu
ncarol.com
  • Home
  • Books
  • Health
  • Book Release
  • Manufacturing
  • Real Estate
  • Business
  • Financial
  • Non-profit
ncarol.com

The ROS1ders Issue RFA for $75K ROS1+ Cancer Innovation Award
ncarol.com/10256312

Trending...
  • New Book, The KI of Marketing, Helps Small Businesses Grow Without Trying to Outspend Bigger Competitors
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
Patient-founded nonprofit seeks to stimulate innovative research to improve outcomes for patients with ROS1+ cancers.

SACRAMENTO, Calif. - ncarol.com -- The ROS1ders is pleased to issue their 2024 Request for Application (RFA) to study ROS1-positive (ROS1+) cancer. The RFA is open to investigators who hold a doctorate degree and a faculty appointment at an academic or non-profit research institution anywhere in the world.

"While oral targeted therapies are approved to treat ROS1+ cancer, the drugs don't work for everyone, and they eventually stop working. We are committed to investing in research to improve patient outcomes," says Janet Freeman-Daily, MS, Engr, co-founder and president of The ROS1ders.

The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward projects focused on ROS1+ cancers. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research.

"Seed grants allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the seeds of real breakthroughs."

More on ncarol.com
  • Gigasoft 2026 JavaScript Chart Comparison: ProEssentials, Highcharts, SciChart, LightningChart, ECharts
  • Experienced eXp Realty Agent Kerri Lawless Guides Buyers and Sellers Through Life's Next Chapters in St. Tammany Parish
  • Supreme Garage Door Repair Redirects Marketing Dollars Into North Texas Communities
  • RAS AP Consulting Spotlights Managed AP Governance™ at Esker All Access
  • ANSI BSR Upholds Appeal of AFDE Member Andrew Sulner, MSFS, JD, finding the AAFS Academy Standards Board (ASB) Violated ANSI Essential Requirements

The award program uses a two-step application process. The deadline for a letter of intent is May 3, 2024. Those invited to submit a full application must provide it by August 4, 2024. For more information, visit https://theros1ders.org/seed-grant-program.

About the ROS1ders

Founded by patients in 2015 and incorporated in 2019, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1200 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.

More on ncarol.com
  • Kentucky's Plane Crash Data Lands Far from the State's Busiest Airports
  • StockResearch AI Initiates Coverage on Apple (AAPL) With New Report Examining Valuation, AI Strategy and Future Growth
  • Netberg Announces the Aurora X2 Switch Series, Built on Xsight Labs' Programmable X2 Silicon
  • Pete Verbica: America Needs Statesmanship and Common Sense — Not a Cult of Personality
  • Heidi G. Villari of The Villari Firm, PLLC Recognized in The Best Lawyers in America 2027 for Construction Law and Personal Injury Litigation

About ROS1+ Cancer
  • ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer (NSCLC). The incidence is thought to be similar in other types of cancer.
  • Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer (NSCLC), but for few other cancers.
  • Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
  • Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.


Contact
Janet Freeman-Daily
***@theros1ders.org


Source: The ROS1ders, Inc.
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
  • New Book, The KI of Marketing, Helps Small Businesses Grow Without Trying to Outspend Bigger Competitors
  • KayeDinero Expands Instrumental Catalog With New Music Released Through I Love Food Media
  • Food Journal Magazine Focuses Its Los Angeles Dining Coverage Across Three Editorial Verticals
  • Where Do Missouri Plane Crashes Really Happen? Not Where You'd Think
  • LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
  • The Sharon at SouthPark Breaks Ground on $178 Million Expansion
  • Pattern Recognition In The Arts
  • Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • Couture Master Perfumer JoAnne Bassett Unveils All-Natural Parfum in Oil Collection in Gift Box
  • Independent Colbert Packaging Thrives Amid Industrywide Consolidation
  • Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
  • STEM For Kids® Unveil Turn-Key "Screen-Smart" Solution to Bridge Teacher Preparedness Gaps in Texas
  • Award-Winning Couture Master Perfumer JoAnne Bassett Launches All-Natural DIY Perfume Making Kits
  • Couture Master Perfumer JoAnne Bassett Offers Rare Opportunity to Acquire 70 Formula Perfume Codex
  • Slotozilla Reports Strong Growth in Q2 2026
  • Flexible Plan Investments Names Carl Resnick President
  • Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
_catLbl0 _catLbl1

Popular on ncarol.com

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 352
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 145
  • Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home - 124
  • Opteamix welcomes Girish Ramachandra to its leadership team as Senior Vice President of Client Services - 114
  • New Research Identifies "The Great Junk Transfer": 49% of Americans Would Rather Inherit Nothing Than Sort Through a Relative's Belongings - 112
  • RAS AP Consulting Expands Managed AP Governance™ Ecosystem, Launches Trademark Process, and Secures IFOL Speaker Invitation - 111
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism - 106
  • UK Financial Ltd Verifies Maya Preferred PRA Circulating Supply, Proving Its Eight-Year Promise of Under 1M Tokens After Chainlink Labs Agreement - 105
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate - 101
  • $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth

Similar on ncarol.com

  • When the Coroner's Report Isn't Enough: Colorado Families Turn to Private Autopsy for Closure
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History
  • New Analysis Details Three Converging Forces in AI and Workforce Policy Behind a $37 Billion GDP Reduction
  • NaturismRE expands international research programme with Health & Wellbeing Survey
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
  • The Sharon at SouthPark Breaks Ground on $178 Million Expansion
  • Independent Colbert Packaging Thrives Amid Industrywide Consolidation
  • Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute